Addressing Involuntary Movements in Tardive Dyskinesia (AIM-TD): Effect of Fixed-Dose Deutetrabenazine by Baseline Comorbidities (S56.006)

Conclusions:Deutetrabenazine provided clinically meaningful improvements in AIMS scores and CGIC regardless of psychiatric illness type, with a favorable safety/tolerability profile.Study Supported by:This study was funded by Teva Branded Pharmaceutical Products R&D, Inc. Petach Tikva, IsraelDisclosure: Dr. Anderson has received personal compensation for activities with LEGATO-HD, AIM-TD, ARM-TD studies. Pride-HD, First-HD, ARC-HD, and Teva CNS> Dr. Factor has received personal compensation for activities with Lundbeck, TEVA, Neurocrine, Avanir, Cynapsus, and Adamas as a consultant and from Uptodate as a speaker. Dr. Factor has received research support from Ipsen, Auspex/Teva, US World Meds, Pharm-Olam, Cynapsus Therapeutics, Solstice, CHDI Foundation, Michael J. Fox Foundation, NIH and Medtronic. Dr. Davis has received personal compensation for activities with Teva Pharmaceuticals as an employee. Dr. Hauser has received personal compensation for activities with Guidepoint Global, SAI-Mmed Partners, Scienomics Group, Gerson Lehrman Group, LCN Consulting, Putnam Associates, National Parkinson Foundation, eResearch Technology, Inc., Lundbeck LLC, Krog & Partners, and Cynapsus as a consultant. Dr. Hauser has received licensing fee payments from the University of South Florida. Dr. Hauser has received research support from Abbvie Pharmaceutical Research and Development, Acadia Pharmaceuticals, Astra Zeneca, Biotie Therapies, Acorda Therapeutics, Inc., Civitas, Impax P...

Source: Neurology - April 17, 2017 Category: Neurology Authors: Anderson, K. E., Factor, S. A., Davis, M. D., Hauser, R. A., Isojarvi, J., Jimenez-Shahed, J., Stamler, D., Ondo, W. G., Fernandez, H. H. Tags: Movement Disorders: Huntington ' s Disease and Drug-Induced Dyskinesias Source Type: research